La maladie de Parkinson en France (serveur d'exploration) - Analysis (UK)

Index « Auteurs » - entrée « David J. Brooks »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
David J. Adams < David J. Brooks < David J. Burn  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
000082 (2015) Zhen Fan [Royaume-Uni] ; Yahyah Aman [Royaume-Uni] ; Imtiaz Ahmed [Royaume-Uni] ; Gaël Chetelat [France] ; Brigitte Landeau [France] ; K. Ray Chaudhuri [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Paul Edison [Royaume-Uni]Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.
000285 (2011) Imtiaz Ahmed [Royaume-Uni] ; Subrata K. Bose [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Anil Ramlackhansingh [Royaume-Uni] ; Federico Turkheimer [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Alexander Hammers [Royaume-Uni, France] ; David J. Brooks [Royaume-Uni]Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
000367 (2009) Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Oliver Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]Validation of the freezing of gait questionnaire in patients with Parkinson's disease
000470 (2006) Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
000516 (2004) Alan L. Whone [Royaume-Uni] ; Dale L. Bailey ; Philippe Remy ; Nicola Pavese ; David J. BrooksA technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
000543 (2003) Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
000635 (1998) A. J. Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study

List of associated KwdEn.i

Nombre de
documents
Descripteur
4Humans
4Levodopa
4Parkinson disease
3Nervous system diseases
3Parkinson Disease (drug therapy)
3Ropinirole
2Antiparkinson Agents (therapeutic use)
2Confidence Intervals
2Dopamine agonist
2Dyskinesia
2Emission tomography
2Human
2Indoles (therapeutic use)
2Levodopa (therapeutic use)
2Longitudinal Studies
2Parkinson Disease (diagnostic imaging)
2Parkinson's disease
2Radiopharmaceuticals
2Treatment Outcome
1Adult
1Aged
1Agonist
1Algorithms
1Alzheimer Disease (diagnostic imaging)
1Alzheimer Disease (immunology)
1Alzheimer Disease (pathology)
1Aminoacid
1Amyloid (metabolism)
1Analysis of Variance
1Antiparkinson Agents (adverse effects)
1Brain (diagnostic imaging)
1Brain (immunology)
1Brain (pathology)
1Brain Mapping
1Canada
1Carbon Radioisotopes
1Cartography
1Catecholamine
1Central nervous system
1Cognitive Dysfunction (diagnostic imaging)
1Cognitive Dysfunction (immunology)
1Cognitive Dysfunction (pathology)
1Comparative study
1D2 Dopamine receptor
1Dihydroxyphenylalanine (analogs & derivatives)
1Disease Progression
1Dopa
1Dopamine
1Dopamine Agents (therapeutic use)
1Dopamine Agonists (therapeutic use)
1Double blind study
1Double-Blind Method
1Double‐blind, controlled study
1Drug Therapy, Combination
1Dyskinesia, Drug-Induced (etiology)
1Dyskinesia, Drug-Induced (mortality)
1Early Parkinson's disease
1Female
1Fluorodeoxyglucose F18
1France
1Freezing
1Germany
1Glucose (metabolism)
1Glutamate
1Glutamate receptor
1Image Interpretation, Computer-Assisted (methods)
1Indoles (adverse effects)
1Isoquinolines
1Levodopa (adverse effects)
1Magnetic Resonance Imaging
1Male
1Microglia (diagnostic imaging)
1Microglia (metabolism)
1Microglia (pathology)
1Middle Aged
1NMDA receptor
1Neuropsychological Tests
1Odds Ratio
1Parkinson Disease (epidemiology)
1Parkinson Disease (immunology)
1Parkinson Disease (mortality)
1Parkinson Disease (pathology)
1Positron
1Positron emission tomography
1Positron-Emission Tomography
1Predictive Value of Tests
1Prognosis
1Proportional Hazards Models
1Putamen
1Questionnaire
1Rasagiline
1Regression Analysis
1Reproducibility of Results
1Risk Factors
1Sensitivity and Specificity
1Severity of Illness Index
1Signal Processing, Computer-Assisted
1Survival Analysis
1Tomography, Emission-Computed (methods)
1United Kingdom

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "David J. Brooks" 
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i  \
                -Sk "David J. Brooks" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    UK
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    David J. Brooks
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024